Laga advises investors’ syndicate on set-up of and investment in Aelin Therapeutics

Taking on your challenges

13 December 2017

Laga advised the investors’ syndicate on the set-up of and investment in Aelin Therapeutics, a spin-off from VIB that received early stage investment for EUR 27M.

The investors’ syndicate includes LSP (Life Sciences Partners, the Netherlands), PMV (Belgium), Novartis Venture Fund (Switzerland), Boehringer Ingelheim Venture Fund (Germany) and Fund+ (Belgium).

Christoph Michiels and Sophie Wyckmans from the Corporate - M&A practice comprised the team.

Did you find this useful?